iiinova — where your digital self keeps evolving

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 19/10/2026

The biology of T follicular helper cells, which support B cell function, changes during ageing. Targeted strategies to modulate their activity are emerging as an attractive therapeutic approach - see this Review in the October issue www.nature.com/articles/s41... rdcu.be/b8VsfUHGjW6a

031 3

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 13/10/2026

Members of the solute carrier (SLC) membrane transporter family are established targets for CNS disorders such as depression. This Review discusses emerging SLC targets for epilepsy, neurodegeneration and autism spectrum disorders nature.com/articles/s41... rdcu.be/PvbB3uJbbxca

010 1

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 05/10/2026

COPD trial wins spur broad respiratory hopes nature.com/articles/d41... AstraZeneca’s tozorakimab reduced disease flare ups in patients with COPD, suggesting IL-33-targeted antibodies could offer broad potential in lung diseases. Read about the COPD pipeline in this news feature

000 0

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 29/09/2026

Our October issue is live! Read about mRNA therapeutics, orexin receptor agonists for narcolepsy, targeting T follicular helper cells, simulation-guided clinical trials and more here nature.com/nrd/volumes/...

000 0

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 21/09/2026

The evolving landscape of drug targets www.nature.com/articles/s41... rdcu.be/22o1FPpNJ3Ga In the past 25 years, advances in areas such as genomics and the diversification of therapeutic modalities have expanded the drug target landscape. It now includes ~700 targets, as mapped in this new Review

Figure showing the drug target landscape by target type and modality

130 3

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 18/09/2026

First myostatin-targeted antibody approved for spinal muscular atrophy nature.com/articles/d41... Scholar Rock’s apitegromab has received FDA approval for SMA. Drug developers hope the drug class could be applied in other settings such as muscle preservation during weight loss

011 1

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 17/09/2026

A translational framework for extrahepatic oligonucleotide delivery nature.com/articles/d41... This Comment article outlines an industry-grade quality framework to eliminate methodological artifacts and ensure the translational and commercial viability of novel oligonucleotide platforms

001 1

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 10/09/2026

For readers interested in the potential of in vivo CAR-T cell therapies for cancer and autoimmune diseases, here's a comprehensive review by pioneers in the field rdcu.be/koc33UDidsza nature.com/articles/s41...

020 2

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 07/09/2026

Un-siloed biomedical opportunities www.nature.com/articles/d41... Edith Heard, CEO of the Francis Crick Institute in London @crick.ac.uk, discusses the need to break down biomedical boundaries

020 2

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 04/09/2026

The FDA recently approved the first orexin receptor agonist for narcolepsy nature.com/articles/d41... Oveporexton is anticipated to transform the treatment of this sleep disorder, and potential additional applications have led to the class being dubbed the GLP-1s of neuroscience

Table of orexin receptor 2 agonists in development

000 0

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 02/09/2026

Solute carrier membrane transporters: emerging targets in CNS disorders www.nature.com/articles/s41... rdcu.be/uQeAYKzFg8Ua This new Review discusses targeting SLC transporters in neurodegenerative diseases, autism spectrum disorders and epilepsy

030 3

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 01/09/2026

For readers interested in JAK inhibitors for autoimmmune diseases, such as Roivant's brepocitinib that has just been approved by the FDA for dermatomyositis, here's a review on pharmacological targeting of the JAK-STAT pathway nature.com/articles/s41... rdcu.be/rpNrcuDMf4ha

042 4

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 01/09/2026

Our September issue is live! Read about brain-shuttle biologics, targeting claudins in cancer, agonist antibody-based immunotherapies, autophagy modulation in cancer and more here nature.com/nrd/volumes/...

000 0

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 21/08/2026

For readers interested in mRNA therapeutics, including neoantigen-based therapeutic cancer vaccines such as Moderna and Merck's intismeran autogene, here's a recent Review www.nature.com/articles/s41... rdcu.be/fBiGZ

Process by which therapeutic mRNA cancer vaccines are produced

020 2

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 12/08/2026

Oncolytic virus nabs FDA approval nature.com/articles/d41... Replimune’s vusolimogene oderparepvec (Tudriqev, also known as RP1) has received accelerated approval for use in combination with the PD-1 blocker nivolumab for advanced melanoma. It is the second oncolytic virus to reach the US market

000 0

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 11/08/2026

For readers interested in targeted protein degradation, this Perspective in the August issue discusses safety considerations in the development of PROTAC and molecule glue drug candidates that recruit the E3 ligase cereblon www.nature.com/articles/s41... rdcu.be/fzgJJ

041 4

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 10/08/2026

Orexin receptor agonist secures landmark narcolepsy approval nature.com/articles/d41... As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists

021 2

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 10/08/2026

Artificial intelligence in drug discovery — what it is, where we stand and the path forward nature.com/articles/s41... rdcu.be/fyUFz

032 3

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 03/08/2026

Multispecific T-cell engagers that bind three or more targets on cancer and immune cells promise to address the shortcomings of their bispecific predecessors - find out more in this news story in our August issue www.nature.com/articles/d41...

Table of multispecific T-cell engagers in development

010 1

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 03/08/2026

Our August issue is live! Read about multispecific T-cell engagers for cancer, the design of small-molecule kinase inhibitors, the evolution of pharmacotherapy for obesity, safety considerations for targeted protein degraders and more here www.nature.com/nrd/volumes/...

000 0

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 30/07/2026

For readers interested in drug discovery targeting GPCRs, this Review covers trends in the field: www.nature.com/articles/s41... rdcu.be/fwSqG and this Review covers opportunities from understanding of functional dynamics: www.nature.com/articles/s41... rdcu.be/fwSrj

040 4

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 15/07/2026

FDA new drug approvals in Q2 2026 www.nature.com/articles/d41... Q2 2026 saw a rebound for novel FDA drug approvals with a total of 13, also with heavy commercial firepower thanks to products such as the first oral small-molecule GLP-1 receptor agonist

000 0

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 14/07/2026

A growing pipeline of multispecific antibody therapies are in clinical trials, showcasing novel biological effects as well as potential improvements over multi-agent cocktails. Find out more in this news story in the July issue www.nature.com/articles/d41...

032 3

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 13/07/2026

Design, simulate, refine: simulation-guided clinical trials for accelerated drug development rdcu.be/ftz8C www.nature.com/articles/s41... This new Perspective discusses the value of trial simulations, presents best-practice recommendations and describes case studies of impact

011 1

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 09/07/2026

For readers interested in therapeutic strategies for chronic obstructive pulmonary disease (COPD), such as PDE3/4 inhibition - the focus of AstraZeneca's latest potential $2.1 billion deal - here's a review www.nature.com/articles/s41... rdcu.be/fs1jW

010 1

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 08/07/2026

CAR T cell therapy for solid cancer scores first approval in China www.nature.com/articles/d41... CARsgen Therapeutics’ claudin18.2-targeted therapy satricabtagene autoleucel has been approved for claudin18.2-positive gastric/gastroesophageal junction adenocarcinoma

001 1

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 06/07/2026

Small-molecule drug candidates increasingly have limited aqueous solubility, making oral delivery challenging. This Perspective in the July issue discusses formulation approaches to mitigate solubility and dissolution rate limitations www.nature.com/articles/s41... rdcu.be/fsjUt

021 2

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 03/07/2026

Our July issue is live! Read about multispecific biologics, AI in target identification and assessment, CDK inhibitors for treating cancer and the role of formulations in oral delivery of poorly water-soluble drugs here www.nature.com/nrd/volumes/...

041 4

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 01/07/2026

Growth in clinical research capability in China and impact on the pharmaceutical sector nature.com/articles/d41... This new article analyses data on the growth in inputs to clinical research capability in China and its impact on outputs such as investigator-initiated trials

001 1

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 19/06/2026

This Nature conference will bring together researchers from academia and industry to explore the evolving landscape of cancer therapeutics. Join us in Houston this October for discussions on next‑generation therapies and emerging approaches. go.nature.com/4daqpHm

000 0

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 19/06/2026

Multispecific T-cell engagers attract cancer drug developers nature.com/articles/d41... Multispecific T-cell engagers that bind three or more targets on cancer and immune cells promise to address the shortcomings of their bispecific predecessors

Schematic with multispecific antibody structures

042 4

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 19/06/2026

Can multispecific biologics break the efficacy ceiling? nature.com/articles/d41... A growing pipeline of multispecific antibody therapies are in clinical trials, showcasing novel biological effects as well as potential improvements over multi-agent cocktails

010 1

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 15/06/2026

Novel drug targets in 2025 www.nature.com/articles/d41... This new article highlights 11 targets not previously modulated by approved drugs

000 0

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 11/06/2026

Antiviral peptide nabs FDA approval for hepatitis delta virus infection www.nature.com/articles/d41... Gilead’s bulevirtide is the first treatment for the potentially fatal infection

122 2

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 09/06/2026

For readers interested in next-generation GLP-1-based therapies for diabetes, obesity and more, here's a review nature.com/articles/s41... rdcu.be/fnl3W

1152 15

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 08/06/2026

A guide to effective drug development through nonprofit models www.nature.com/articles/d41... Patient organizations are reshaping rare disease drug development. Based on a survey, interviews and experience, this article discusses how to direct resources toward drug development goals

010 1

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 08/06/2026

Our June issue is live! Read about the therapeutic potential of orphan GPCRs, wearable technologies in clinical trials for drug development, a renaissance in targeting the PI3K/AKT/mTOR pathway and more here www.nature.com/nrd/volumes/...

032 3

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 04/06/2026

Therapeutic and prophylactic strategies for Ebola caused by Bundibugyo virus www.nature.com/articles/d41... This new article argues that the ongoing Ebola outbreak should be a turning point for moving R&D towards species-inclusive and broadly applicable filovirus countermeasures

000 0

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 03/06/2026

Better data for better medicines: a path to data-driven medicines regulation www.nature.com/articles/d41... This new Comment article highlights how the EU medicines regulatory system is becoming more data-driven

001 1

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 03/06/2026

Towards mRNA therapeutics 2.0 www.nature.com/articles/s41... This new Review discusses progress and insights from clinical studies on mRNA-based drugs, including enzyme replacement therapies, cancer immunotherapies, genome-modifying therapies and immune cell reprogramming therapies

051 5

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 29/05/2026

Targeting claudins in cancer www.nature.com/articles/s41... rdcu.be/flf2S Claudins, which are key regulators of epithelial function, are emerging as targets in cancer, validated by the approval of a CLDN18.2-targeted drug. This new Review discusses progress in the field #ASCO26

032 3

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 27/05/2026

This Review in the May issue discusses how microglia integrate signals from central and peripheral immune cells in neurodegenerative disorders, highlighting therapeutic targets and biomarkers www.nature.com/articles/s41... rdcu.be/fk3uL

Neuroimmune mechanisms in neurodegeneration

053 5

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 26/05/2026

Antibody-based extracellular targeted protein degraders that destroy disease-linked proteins in cancer and autoimmunity are advancing in the clinic. Find out more in this news story in our May issue www.nature.com/articles/d41...

Table of biologic targeted protein degraders

020 2

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 20/05/2026

FDA approves first-in-class hypertension drug www.nature.com/articles/d41... AstraZeneca’s baxdrostat is the first aldosterone synthase inhibitor to be approved, providing a new way to lower blood pressure. Peak sales >$5 billion are forecasted, but two competitors are close behind

021 2

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 12/05/2026

Blood–brain barrier (BBB) dysfunction is a hallmark of many diseases of the brain, such as Alzheimer disease. This Review in the May issue covers strategies for BBB repair and protection in various diseases and during normal ageing rdcu.be/fij4F www.nature.com/articles/s41...

011 1

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 07/05/2026

Our May issue is live! Read about biologic targeted protein degraders, strategies for blood-brain barrier rejuvenation and repair, targeting extrachromosomal DNA in cancer, therapeutic targeting of neuroimmune mechanisms in neurodegeneration and more here nature.com/nrd/volumes/...

030 3

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 06/05/2026

For readers interested in drug repurposing, this Review evaluates computational approaches to drug repurposing based on categorization of available resources into an online catalogue www.nature.com/articles/s41... rdcu.be/fhe2Z

Computational resources for drug repurposing categorized by type

021 2

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 06/05/2026

Bridging boundaries: making drug repurposing the new normal nature.com/articles/d41... This new article discusses approaches to overcoming systemic challenges in drug repurposing, enabling the approach to contribute more to new therapies, especially for rare diseases

000 0

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 05/05/2026

Shifts in pharma’s therapeutic area focus www.nature.com/articles/d41... This new article analyses the evolution of the therapeutic area focus of large pharmaceutical companies, as well as phase III resourcing and the composition of drug launches

Composition and global revenue share of top 100 launches by product type

130 3

Nature Reviews Drug Discovery @natrevdrugdiscov.nature.com · 27/04/2026

In vivo CAR T purchase spree continues with Lilly deal worth up to US$7 billion www.nature.com/articles/d41... The deal is the biggest to date in the red-hot race to develop therapies that reprogram immune cells directly in patients for the treatment of cancer and autoimmune diseases

010 1